Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds

被引:112
作者
Enokizono, Junichi [1 ]
Kusuhara, Hiroyuki [1 ]
Ose, Atsushi [1 ]
Schinkel, Alfred H. [2 ]
Sugiyama, Yuichi [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1124/dmd.107.019257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of breast cancer resistance protein (BCRP/ABCG2) in limiting the brain and testis penetration of xenobiotic compounds in the blood-brain and -testis barriers was investigated using Bcrp(-/-) mice. Tissue/plasma concentration ratios in the brain (K-p,K-brain) and testis ( K-p,K-testis) obtained under steady-state conditions were significantly increased in Bcrp(-/-) mice for PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), N-hydroxyl PhIP, MeIQx (2-amino3,8-dimethylimidazo[4,5-f]quinoxaline), dantrolene, and prazosin. In addition, the K-p,K-brain of triamterene and the K-p,K-testis of 4 '-hydroxyl PhIP were also significantly increased in Bcrp(-/-) mice. The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp(-/-) mice determined using in situ brain perfusion was weaker than that observed on the Kp values. In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein. The Kp values of common substrates exhibited a smaller increase both in the brain and testis of Bcrp(-/-) mice than expected from the in vitro Bcrp activities. The Bcrp-specific substrates were weak acids, whereas basic or neutral BCRP substrates were also P-glycoprotein substrates. These results suggest that BCRP limits the tissue penetration of xenobiotic compounds in the blood-brain and-testis barriers, but its in vivo importance is also modulated by P-glycoprotein activity.
引用
收藏
页码:995 / 1002
页数:8
相关论文
共 42 条
  • [1] Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen
    Adachi, Y
    Suzuki, H
    Schinkel, AH
    Sugiyama, Y
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (03) : 923 - 928
  • [2] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein
    Adachi, Y
    Suzuki, H
    Sugiyama, Y
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (12) : 1660 - 1668
  • [3] Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones
    Ando, Tomohiro
    Kusuhara, Hiroyuki
    Merino, Gracia
    Alvarez, Ana I.
    Schinkel, Alfred H.
    Sugiyama, Yuichi
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) : 1873 - 1879
  • [4] Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier
    Augustine, LM
    Markelewicz, RJ
    Boekelheide, K
    Cherrington, NJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) : 182 - 189
  • [5] Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione
    Bai, J
    Lai, LQ
    Yeo, HC
    Goh, BC
    Tan, TMC
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (02) : 247 - 257
  • [6] The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours
    Bart, J
    Hollema, H
    Groen, HJM
    de Vries, EGE
    Hendrikse, NH
    Sleijfer, DT
    Wegman, TD
    Vaalburg, W
    van der Graaf, WTA
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (14) : 2064 - 2070
  • [7] An oncological view on the blood-testis barrier
    Bart, J
    Groen, HJM
    van der Graaf, WTA
    Hollema, H
    Hendrikse, NH
    Vaalburg, W
    Sleijfer, DT
    de Vries, EGE
    [J]. LANCET ONCOLOGY, 2002, 3 (06) : 357 - 363
  • [8] Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier
    Bihorel, Sebastien
    Camenisch, Gian
    Lemaire, Michel
    Scherrmann, Jean-Michel
    [J]. JOURNAL OF NEUROCHEMISTRY, 2007, 102 (06) : 1749 - 1757
  • [9] The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
    Breedveld, P
    Pluim, D
    Cipriani, G
    Wielinga, P
    van Tellingen, O
    Schinkel, AH
    Schellens, JHM
    [J]. CANCER RESEARCH, 2005, 65 (07) : 2577 - 2582
  • [10] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
    Burger, H
    van Tol, H
    Boersma, AWM
    Brok, M
    Wiemer, EAC
    Stoler, G
    Nooter, K
    [J]. BLOOD, 2004, 104 (09) : 2940 - 2942